• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    7/11/23 1:26:50 PM ET
    $ABOS
    $ADCT
    $ADIL
    $ADN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABOS alert in real time by email

    Gainers

    • CytoMed Therapeutics Limited (NASDAQ:GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.
    • Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) gained 58.2% to $0.32 after the company issued a business update following favorable comments from US and EU regulatory meetings.
    • SOS Limited (NYSE:SOS) climbed 49.2% to $8.52.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) shares climbed 42.2% to $1.2805 after the FDA approved the company's AspyreRx (formerly BT-001), a prescription-only digital treatment to provide cognitive behavioral therapy to adult patients with type 2 diabetes.
    • Taoping Inc. (NASDAQ:TAOP) gained 34.4% to $0.7099. Taoping posted 1H contract revenue of $14.65 million, up 95% year over year.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares climbed 29.6% to $0.57.
    • Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) rose 29.4% to $5.06 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $50 to $55.
    • Vivakor, Inc. (NASDAQ:VIVK) gained 21.6% to $1.29.
    • AgeX Therapeutics, Inc. (NYSE:AGE) rose 18.4% to $0.90.
    • The9 Limited (NASDAQ:NCTY) gained 18.2% to $1.1299.
    • Nuvve Holding Corp. (NASDAQ:NVVE) climbed 16.5% to $0.7927. Nuvve introduced artificial intelligence into its GIVe software platform via integration into the fleetbox charge management app.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) gained 16.7% to $0.8980.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) rose 15.4% to $7.55.
    • Virios Therapeutics, Inc. (NASDAQ:VIRI) rose 14.4% to $1.74.
    • Hesai Group (NASDAQ:HSAI) gained 14.4% to $12.34.
    • WD-40 Company (NASDAQ:WDFC) jumped 11.8% to $216.70 after the company reported third quarter results that topped expectations.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) gained 10.7% to $0.1749 after jumping around 37% on Monday.
    • Newell Brands Inc. (NASDAQ:NWL) jumped 10.1% to $9.78. Canaccord Genuity initiated coverage on Newell Brands with a Buy rating and announced a price target of $13.
    • Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares climbed 9.8% to $5.45. Acumen Pharmaceuticals recently announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
    • AirSculpt Technologies, Inc. (NASDAQ:AIRS) gained 9.7% to $9.22. AirSculpt Technologies said it expects above-consensus second-quarter revenues and reiterated its 2023 outlook.
    • Zillow Group, Inc. (NASDAQ:ZG) gained 9.4% to $51.00.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares gained 8.8% to $0.1110 after declining around 14% on Monday.
    • Etsy, Inc. (NASDAQ:ETSY) rose 8.3% to $93.01. JMP Securities reiterated Etsy with a Market Outperform and maintained a $130 price target.

    Losers

    • Journey Medical Corporation (NASDAQ:DERM) shares fell 28.9% to $2.02. Journey Medical said its Phase 3 trials evaluating DFD-29 for the treatment of papulopustular rosacea in adults achieved co-primary and all secondary endpoints.
    • Siyata Mobile Inc. (NASDAQ:SYTA) shares tumbled 21.1% to $0.0571 after the company reported pricing of $2.3 million registered direct of 51,450,000 common shares for $0.045 per share.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) shares declined 20% to $2.1990.
    • ADC Therapeutics SA (NASDAQ:ADCT) fell 19.8% to $1.90 after the company paused enrollment in Phase 2 LOTIS-9 trial of Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large b-cell lymphoma.
    • DSS, Inc. (NYSE:DSS) fell 17.1% to $0.3002. DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc, recently named Daniel Lew as Chief Investment Officer and Portfolio Manager.
    • Byrna Technologies Inc. (NASDAQ:BYRN) declined 16.8% to $4.34. Byrna Technologies posted downbeat second-quarter results and withdrew guidance for fiscal year 2023.
    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 16% to $0.1765 after declining 19% on Monday. Tattooed Chef recently announced it intends to file for voluntary Chapter 11 Bankruptcy protection.
    • Mobilicom Limited (NASDAQ:MOB) fell 14.1% to $2.42. Mobilicom recently announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) fell 13.7% to $0.4745. Jupiter Wellness shares jumped over 50% on Monday after the company announced it has executed an Asset Purchase Agreement with GBB Drink Lab to acquire all operating assets including the "Safety Shot" rapid alcohol detox drink.
    • BioRestorative Therapies, Inc. (NASDAQ:BRTX) declined 13.4% to $3.08 after the company announced a $2.1 million registered direct offering.
    • Viridian Therapeutics, Inc. (NASDAQ:VRDN) fell 13.4% to $21.18 after announcing data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients with chronic thyroid eye disease.
    • VOXX International Corporation (NASDAQ:VOXX) shares declined 11.8% to $10.00 as the company posted downbeat results for its third quarter on Monday.
    • urban-gro, Inc. (NASDAQ:UGRO) shares fell 11.1% to $1.77 after rising around 5% on Monday.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) fell 10.3% to $1.30. Salarius Pharmaceuticals received FDA clearance of SP-3164 investigational new drug application to begin a Phase 1 clinical trial in relapsed/refractory non-hodgkin lymphoma patients.
    • Carisma Therapeutics, Inc. (NASDAQ:CARM) fell 8.7% to $8.56.
    • Century Aluminum Company (NASDAQ:CENX) fell 8.5% to $8.06. Wolfe Research downgraded Century Aluminum from Peer Perform to Underperform and announced a $6 price target.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell 8.4% to $8.06 as the company priced its underwritten public offering of 20,000,000 shares at $7.50 per share.
    • VeriSign, Inc. (NASDAQ:VRSN) fell 5.1% to $213.66. Baird downgraded VeriSign from Outperform to Neutral and lowered the price target from $265 to $245.

     

    Now Read This: More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $ADCT
    $ADIL
    $ADN

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Etsy Inc.
    $ETSY
    2/20/2026$72.00Equal Weight → Overweight
    Barclays
    Hesai Group
    $HSAI
    2/10/2026$31.50Outperform
    Macquarie
    Zillow Group Inc.
    $ZG
    1/29/2026$72.00Underweight → Equal Weight
    Barclays
    Zillow Group Inc.
    $ZG
    1/14/2026$85.00Outperform
    BNP Paribas Exane
    Zillow Group Inc.
    $ZG
    1/9/2026$70.00Outperform → Neutral
    Mizuho
    Viridian Therapeutics Inc.
    $VRDN
    12/10/2025$42.00 → $47.00Outperform
    Wedbush
    Viridian Therapeutics Inc.
    $VRDN
    12/3/2025Outperform
    William Blair
    More analyst ratings

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Acumen Pharmaceuticals Inc.

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    3/10/26 9:45:26 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Patel Goyal Kruti

    4 - ETSY INC (0001370637) (Issuer)

    3/10/26 4:36:48 PM ET
    $ETSY
    Real Estate

    SEC Form 4 filed by Etsy Inc.

    4 - ETSY INC (0001370637) (Issuer)

    3/10/26 4:35:03 PM ET
    $ETSY
    Real Estate

    $ABOS
    $ADCT
    $ADIL
    $ADN
    SEC Filings

    View All

    SEC Form S-3 filed by ADC Therapeutics SA

    S-3 - ADC Therapeutics SA (0001771910) (Filer)

    3/10/26 5:09:40 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ADC Therapeutics SA

    10-K - ADC Therapeutics SA (0001771910) (Filer)

    3/10/26 4:36:47 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    3/10/26 7:58:12 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

    NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026, at 11:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid

    3/10/26 4:00:00 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f

    3/10/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUVVE JAPAN Finalizes First Sale Agreement for 2MW / 8MWh Battery Storage Project in Mino, Gifu for $3.35 million (¥520 Million)

    NUVVE JAPAN K.K. ("NUVVE JAPAN"), the Japanese subsidiary of Nuvve Holding Corp. (NASDAQ:NVVE), a global leader in grid modernization and energy storage including vehicle-to-grid (V2G) technology, is pleased to announce that it has entered into a definitive sales agreement for its front-of-the-meter battery energy storage system (BESS) for a project located in Mino City, Gifu Prefecture. The project features a power output of 2MW and a storage capacity of 8MWh with a contracted sale price of $3.35M (¥520M). The project is anticipated to be operational during the fourth quarter of 2026. Strategic Background and Financial Impact NUVVE JAPAN is dedicated to expanding the adoption of rene

    3/9/26 9:00:00 AM ET
    $NVVE
    Electrical Products
    Industrials

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Etsy upgraded by Barclays with a new price target

    Barclays upgraded Etsy from Equal Weight to Overweight and set a new price target of $72.00

    2/20/26 8:19:45 AM ET
    $ETSY
    Real Estate

    Macquarie initiated coverage on Hesai Group with a new price target

    Macquarie initiated coverage of Hesai Group with a rating of Outperform and set a new price target of $31.50

    2/10/26 9:51:02 AM ET
    $HSAI
    Industrial Machinery/Components
    Industrials

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Director Armstrong Courtney D bought $4,912 worth of shares (22 units at $222.94), increasing direct ownership by 0.37% to 882 units (SEC Form 4)

    4 - VERISIGN INC/CA (0001014473) (Issuer)

    3/3/26 4:49:10 PM ET
    $VRSN
    EDP Services
    Technology

    $ABOS
    $ADCT
    $ADIL
    $ADN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Leadership Updates

    Live Leadership Updates

    View All

    Byrna Technologies Announces CEO Transition

    Transformational Leader Bryan Ganz to Retire as CEO  Conn Davis Appointed as Successor TJ Kennedy Appointed Chair of the Board ANDOVER, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. ("Byrna" or the "Company") (NASDAQ:BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that Bryan Ganz is retiring as Chief Executive Officer and as a member of the Company's Board of Directors. Following an extensive search process, with the assistance of a leading independent search firm, the Byrna Board has appointed Conn Davis to succeed Mr. Ganz and join the Bo

    3/3/26 8:00:00 AM ET
    $BYRN
    Industrial Machinery/Components
    Miscellaneous

    WD-40 Company Announces Board Changes

    WD-40 Company (NASDAQ:WDFC), a global marketing organization dedicated to creating positive lasting memories by developing and selling products that solve problems in workshops, factories, and homes around the world, announced today the appointment of Ken Plunk to its board of directors, effective February 18, 2026. Mr. Plunk will serve as a member of the Audit and Finance Committees. Mr. Plunk is an experienced board member with deep expertise in finance, strategy, governance, and risk management. He is known for his ability to lead organizational transformations and execute strategic initiatives that improve financial performance and shareholder value across complex, global businesses.

    2/19/26 4:05:00 PM ET
    $WDFC
    Major Chemicals
    Industrials

    Etsy Announces New $750 Million Share Repurchase Authorization and appointment of Fred Wilson as Lead Independent Director

    BROOKLYN, N.Y., Dec. 18, 2025 /PRNewswire/ -- Etsy, Inc. (NYSE:ETSY), the global marketplace for unique and creative goods, today announced that its Board of Directors has approved a new $750 million share repurchase authorization. When combined with the estimated remaining capacity of over $200 million1 under the Company's existing share repurchase Board authorization, Etsy will have authorization for close to $1 billion of potential future share repurchases. In addition, the Board has appointed the current Chair of the Board, Fred Wilson, as Lead Independent Director effective January 1, 2026. The appointment follows the previously announced leadership transition in which Kruti Patel Goya

    12/18/25 7:00:00 AM ET
    $ETSY
    Real Estate

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by DSS Inc.

    SC 13D/A - DSS, INC. (0000771999) (Subject)

    12/12/24 9:56:52 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Financials

    Live finance-specific insights

    View All

    ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f

    3/10/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Byrna Technologies Announces Preliminary Fiscal First Quarter Revenues of $29.0 Million

    ANDOVER, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. ("Byrna" or the "Company") (NASDAQ:BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced select preliminary financial results for the fiscal first quarter ended February 28, 2026. Preliminary First Quarter ResultsBased on preliminary unaudited results, Byrna expects total revenue for the fiscal first quarter of 2026 to be approximately $29.0 million, an increase of 11% compared to $26.2 million in the fiscal first quarter of 2025. The Company also ended the quarter with approximately $1.1 million in

    3/9/26 8:00:00 AM ET
    $BYRN
    Industrial Machinery/Components
    Miscellaneous

    Hesai Group to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, March 24, 2026

    SHANGHAI, China, March 04, 2026 (GLOBE NEWSWIRE) -- Hesai Group ("Hesai," "Hesai Technology" or the "Company") (NASDAQ:HSAI, HKEX: 2525)), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced that it will report its fourth quarter and full year 2025 unaudited financial results on Tuesday, March 24, 2026, before the U.S. market opens. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 24, 2026 (8:00 PM Beijing/Hong Kong Time on March 24, 2026). For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration and dial in 5 minutes pri

    3/4/26 3:30:00 AM ET
    $HSAI
    Industrial Machinery/Components
    Industrials

    $ABOS
    $ADCT
    $ADIL
    $ADN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary